1. |
Richter GM, Palmaz JC, Nöldge G, et al. The transjugular intrahepatic portosystemic stent-shunt. A new nonsurgical percutaneous method. Radiologe, 1989, 29(8):406-411.
|
2. |
Richter GM, Noeldge G, Palmaz JC, et al. Transjugular intrahepatic portacaval stent shunt:preliminary clinical results. Radiology, 1990, 174(3 Pt 2):1027-1030.
|
3. |
Lau CT, Scott M, Stavropoulos SW, et al. Dacron-covered stentgrafts in transjugular intrahepatic portosystemic shunts:initial experience. Radiology, 2005, 236(2):725-729.
|
4. |
Angermayr B, Cejna M, Koenig F, et al. Survival in patients undergoing transjugular intrahepatic portosystemic shunt:ePTFEcovered stentgrafts versus bare stents. Hepatology, 2003, 38(4):1043-1050.
|
5. |
Perarnau JM, Le Gouge A, Nicolas C, et al. Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt:a randomized controlled trial. J Hepatol, 2014, 60(5):962-968.
|
6. |
Sommer CM, Gockner TL, Stampfl U, et al. Technical and clinical outcome of transjugular intrahepatic portosystemic stent shunt:bare metal stents (BMS) versus viatorr stent-grafts (VSG). Eur J Radiol, 2012, 81(9):2273-2280.
|
7. |
Boyer TD, Haskal ZJ; American Association for the Study of Liver Diseases. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension:update 2009. Hepatology, 2010, 51(1):306.
|
8. |
de Franchis R, Baveno V Faculty. Revising consensus in portal hypertension:report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol, 2010, 53(4):762-768.
|
9. |
Roessle M. TIPS:25 years later. J Hepatol, 2013, 59(5):1081-1093.
|
10. |
Zheng M, Chen Y, Bai J, et al. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy in the secondary prophylaxis of variceal rebleeding in cirrhotic patients:meta-analysis update. J Clin Gastroenterol, 2008, 42(5):507-516.
|
11. |
Luca A, D'Amico G, La Galla R, et al. TIPS for prevention of recurrent bleeding in patients with cirrhosis:meta-analysis of randomized clinical trials. Radiology, 212(2):411-421.
|
12. |
Burroughs AK, Vangeli M. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy:randomized trials for secondary prophylaxis of variceal bleeding:an updated meta-analysis. Scand J Gastroenterol, 2002, 37(3):249-252.
|
13. |
Rosemurgy AS, Serafini FM, Zweibel BR, et al. Transjugular intrahepatic portosystemic shunt vs. small-diameter prosthetic H-graft portacaval shunt:extended follow-up of an expanded randomized prospective trial. J Gastrointest Surg, 2001, 4(6):589-597.
|
14. |
Henderson JM, Boyer TD, Kutner MH, et al. Distal splenorenal shunt versus transjugular intrahlepatic portal systematic shunt for variceal bleeding:a randomized trial. Gastroenterology, 2006, 130(6):1643-1651.
|
15. |
Boyer TD, Henderson JM, Heerey AM, et al. Cost of preventing variceal rebleeding with transjugular intrahepatic portal systemic shunt and distal splenorenal shunt. J Hepatol, 2008, 48(3):407-414.
|
16. |
Monescillo A, Martínez-Lagares F, Ruiz-Del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology, 2004, 40(4):793-801.
|
17. |
García-Pagán JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med, 2010, 362(25):2370-2379.
|
18. |
García-Pagán JC, Di Pascoli M, Caca K, et al. Use of early-TIPS for high-risk variceal bleeding:results of a post-RCT surveillance study. J Hepatol, 2013, 58(1):45-50.
|
19. |
Ginès P, Titó L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology, 1988, 94(6):1493-1502.
|
20. |
Rössle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax:a critical update. Gut, 2010, 59(7):988-1000.
|
21. |
Russo MW, Sood A, Jacobson IM, et al. Transjugular intrahepatic portosystemic shunt for refractory ascites:An analysis of the literature on efficacy, morbidity, and mortality. Am J Gastroenterol, 2003, 98(11):2521-2527.
|
22. |
Salerno F, Cammà C, Enea M, et al. Transjugular intrahepatic portosystemic shunt for refractory ascites:a meta-analysis of individual patient data. Gastroenterology, 2007, 133(3):825-834.
|
23. |
Gerbes AL, Sauerbruch T, Dathe K. Method report:German S3-guideline "ascites, spontaneous bacterial peritonitis, hepatorenal syndrome". Z Gastroenterol, 2011, 49(6):780-787.
|
24. |
Michl P, Gülberg V, Bilzer M, et al. Transjugular intrahepatic portosystemic shunt for cirrhosis and ascites:Effects in patients with organic or functional renal failure. Scand J Gastroenterol, 2000, 35(6):654-658.
|
25. |
Brensing KA, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome:a phaseⅡstudy. Gut, 2000, 47(2):288-295.
|
26. |
Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology, 2004, 40(1):55-64.
|
27. |
Testino G, Ferro C, Sumberaz A, et al. Type-2 hepatorenal syndrome and refractory ascites:Role of transjugular intrahepatic portosysternic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology, 2003, 50(54):1753-1755.
|
28. |
Tsauo J, Weng NN, Ma HY, et al. Role of transjugular intrahepatic portosystemic shunts in the management of hepatopulmonary syndrome:a systemic literature review. J Vasc Interv Radiol, 2015, 26(9):1266-1271.
|
29. |
Gordon FD, Anastopoulos HT, Crenshaw W, et al. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology, 1997, 25(6):1366-1369.
|
30. |
Jeffries MA, Kazanjian S, Wilson M, et al. Transjugular intrahepatic portosystemic shunts and liver transplantation in patients with refractory hepatic hydrothorax. Liver Transpl Surg, 1998, 4(5):416-423.
|
31. |
Spencer EB, Cohen DT, Darcy MD. Safety and efficacy of transjugular intrahepatic portosystemic shunt creation for the treatment of hepatic hydrothorax. J Vasc Interv Radiol, 2002, 13(4):385-390.
|
32. |
Wilputte JY, Goffette P, Zech F, et al. The outcome after transjugular intrahepatic portosystemic shunt (TIPS) for hepatic hydrothorax is closely related to liver dysfunction:a long-term study in 28 patients. Acta Gastroenterol Belg, 2007, 70(1):6-10.
|
33. |
Dhanasekaran R, West JK, Gonzales PC, et al. Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis. Am J Gastroenterol, 2010, 105(3):635-641.
|
34. |
Rössle M, Olschewski M, Siegerstetter V, et al. The Budd-Chiari syndrome:outcome after treatment with the transjugular intrahepatic portosystemic shunt. Surgery, 2004, 135(4):394-403.
|
35. |
Valla DC. Budd-Chiari syndrome and veno-occlusive disease/sinusoidal obstruction syndrome. Gut, 2008, 57(10):1469-1478.
|
36. |
Garcia-Pagán JC, Heydtmann M, Raffa S, et al. TIPS for Budd-Chiari syndrome:long-term results and prognostics factors in 124 patients. Gastroenterology, 2008, 135(3):808-815.
|
37. |
Luca A, Caruso S, Milazzo M, et al. Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology, 2012, 265(1):124-132.
|
38. |
Werner KT, Sando S, Carey EJ, et al. Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation:outcome of anticoagulation. Dig Dis Sci, 2013, 58(6):1776-1780.
|
39. |
Chen H, Qi X, He C, et al. Coagulation imbalance may not contribute to the development of portal vein thrombosis in patients with cirrhosis. Thromb Res, 2013, 131(2):173-177.
|
40. |
Luca A, Miraglia R, Caruso S, et al. Short-and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut, 2011, 60(6):846-852.
|
41. |
Luo XE, Wang Z, Tsauo J, et al. Advanced cirrhosis combined with portal vein thrombosis:a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology, 2015, 276(1):286-293.
|